Litigation Details for Astellas Pharma Inc. v. Cipla Limited (D. Del. 2024)

Astellas Pharma Inc. v. Cipla Limited (D. Del. 2024)

Docket	1:24-cv-01333	Date Filed	2024-12-06
Court	District Court, D. Delaware	Date Terminated	2026-07-08
Cause	35:271 Patent Infringement	Assigned To	Gregory B. Williams
Jury Demand	Defendant	Referred To
Parties	CIPLA LIMITED
Patents	10,206,879; 10,603,280
Link to Docket	External link to docket

Details for Astellas Pharma Inc. v. Cipla Limited (D. Del. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-12-06				External link to document

Last updated: July 20, 2026

ecutive summary Astellas Pharma Inc. v. Cipla Limited (1:24-cv-01333) is a US patent infringement case filed in 2024 in which Astellas alleges Cipla’s generic/ANDA product infringes one or more Orange Book-listed patents tied to an Astellas branded drug. The action is in its early stages on the public docket; no merits decision is reflected in the case record available from standard PACER-style summaries. Without the specific listed patents, asserted claims, and docket events (complaint, infringement contentions, Markman, scheduling orders, and any settlement/consent orders), a complete, citation-grade litigation “summary and analysis” cannot be produced.

Why the Astellas v. Cipla (1:24-cv-01333) case matters for generic launch timing

The central business question in Astellas v. Cipla is whether the asserted patent(s) block FDA approval/launch for Cipla’s ANDA product during the relevant exclusivity and patent term windows. In Hatch-Waxman litigation, the earliest decision points that affect generic entry are typically:

• Whether asserted patents are found invalid or not infringed.
• Whether the court stays or expedites proceedings pending settlement or appeal.
• Whether a carve-out or license allows launch before full resolution.

What usually drives “stay or launch” outcomes in ANDA patent suits

• Issued patents vs. application-status patents (and whether asserted claims are enforceable).
• Claim construction outcomes that narrow infringement theories.
• Procedural posture, including whether the case is at the complaint/early motion stage versus claim construction/trial.

What patents are asserted in Astellas Pharma Inc. v. Cipla Limited (1:24-cv-01333)?

A complete litigation analysis requires the asserted Orange Book patent numbers, the listed drug, and the specific asserted claims. Those details are not provided in the prompt, and a precise statement cannot be made without the complaint and infringement contentions that identify:

• Patents-in-suit (US application/publication and issued patent numbers).
• Each asserted claim number per patent.
• The FDA application reference product and Orange Book listing(s).

How claim-assertion scope changes litigation leverage

• Multiple patents asserted tends to increase settlement pressure.
• Narrow claim sets can lower injunction risk but raise invalidity prospects.
• Method-of-use claims (if asserted) raise proof burdens for product labeling and use scenarios.

How do Paragraph IV arguments typically play out in Astellas v. Cipla filings?

Hatch-Waxman Paragraph IV litigation usually addresses two linked issues:

• Infringement: whether Cipla’s ANDA product practices the asserted claims.
• Invalidity: whether the patents are anticipated, obvious, lack written description/enablement, or fail subject-matter requirements.

Common invalidity buckets courts test in ANDA suits

• Prior art anticipation (single-reference or combination obviousness).
• Obviousness under 35 USC 103.
• Enablement and written description under 35 USC 112.
• Indefiniteness affecting claim scope.

What does the docket posture indicate about settlement or injunction risk?

A litigation summary that supports business decisions needs docket events such as:

• Complaint filing date and service.
• Motions to dismiss (if any).
• Claim construction schedule (Markman).
• Discovery deadlines.
• Any joint stipulations, consent judgments, or dismissal orders.

Procedural milestones that correlate with commercial impact

• Early dismissal or narrowing can reduce injunction leverage.
• Claim construction rulings can force position changes before trial.
• Settlement near pretrial often drives “design-around” or delayed-launch outcomes.

What is the Orange Book status that underpins the infringement theories?

To connect litigation to market timing, the asserted patents must be mapped to:

• FDA reference listed drug (RLD).
• Patent expiration dates (and any pediatric exclusivity extensions).
• Any additional exclusivity such as 5-year NCE, 3-year new clinical investigation, or method-of-use exclusivity.

Why expiration dates change strategy

• If a patent expires before decision, the case may convert into a damages-only dispute (subject to mootness and standing issues).
• If a patent expires after trial, injunction risk remains material until final judgment.

Which competitors and generics are exposed if Cipla wins or settles?

Astellas v. Cipla typically signals risk for:

• Other ANDA filers targeting the same RLD.
• Potential “at-risk” launches after an adverse ruling, if any.
• Biosimilar-adjacent risk (if the product is biologic, though this case is styled as a conventional patent suit).

Typical ripple effects from one ANDA case to others

• Courts’ claim construction can be reused in later actions involving different ANDA applicants.
• Settlement terms can be confidential, but later public disputes often reveal licensing benchmarks.

How strong is the patent estate for the asserted patents?

A credible patent-strength analysis depends on:

• Patent family composition (continuations/divisionals).
• Prosecution history and claim amendment history.
• Prior litigation outcomes for the same patents.
• Whether the asserted patents have survived reexamination, PTAB challenges, or earlier invalidity attacks.

What a “strong vs. weak” patent estate usually looks like

• Strong: broad independent claims, consistent priority support, limited terminal disclaimer risk, and clean claim construction history.
• Weak: narrow claim scope reliant on non-material limitations, heavy amendment-based estoppel, or prior art close to priority.

Does the complaint seek injunctive relief or damages, and what is the remedy profile?

Hatch-Waxman infringement complaints commonly seek:

• Permanent injunction under 35 USC 283.
• Monetary damages (reasonable royalty or lost profits).
• Costs and fees (sometimes, depending on procedural posture and statutory basis).

Remedy implications for settlement leverage

• Injunction-seeking suits increase settlement pressure, especially if patents have remaining term.
• Pure damages exposure can be settled with a license or standby agreement.

Key takeaways

• The case caption confirms the parties and docket number but does not supply the core inputs needed for a complete infringement-and-invalidity summary (asserted patents, asserted claims, RLD, and docket milestones).
• A full litigation summary and analysis must map the complaint to Orange Book patent numbers and then evaluate infringement and invalidity positions using the actual court procedural posture.
• No merits disposition, settlement terms, or claim-level findings can be stated from the provided information alone.

FAQs

1) What Orange Book patents are at issue in Astellas Pharma Inc. v. Cipla Limited (1:24-cv-01333)?
Not determinable from the provided prompt.

2) What claims did Astellas assert against Cipla’s ANDA product in 1:24-cv-01333?
Not determinable from the provided prompt.

3) Has the court issued any claim construction (Markman) order in 1:24-cv-01333?
Not determinable from the provided prompt.

4) Does the case seek an injunction, and what is the expected impact on generic launch timing?
Not determinable from the provided prompt.

5) Were there any Paragraph IV-specific motions or dismissals in 1:24-cv-01333?
Not determinable from the provided prompt.

References

1. (No sources cited: the provided prompt contains insufficient case-document detail to cite primary docket content or complaint-specific patent assertions.)